Allscripts-Misys Healthcare Solutions, Inc. (MDRX) has recently expanded its agreement with The Jackson Clinic. Per the agreement, The Jackson Clinic has selected the Allscripts Electronic Health Record (EHR) solution for its 120 physicians and 10 mid-level providers who serve patients throughout West Tennessee, United States. Financial terms of the agreement have not been disclosed. 

The Jackson Clinic has used Misys EMR solutions. It has now decided to integrate Allscripts’ EHR solution with Allscripts’ Vision Practice Management solution to provide full-spectrum automation of all clinical and financial activities. 

Allscripts’ EHR is a software that automates the process of writing prescriptions. The EHR system enables physicians to send prescriptions directly to a pharmacy by e-mail. It has been proven that the effective use of EHR systems reduces medical errors, enhances clinical quality and leads to better patient outcomes by providing real-time access to patient records. 

The U.S. government is increasingly emphasizing the use of EHR systems these days, as evident from the Medicare Improvements for Patients and Providers Act of 2008. For the first time ever, the Act provides financial incentives to physicians who adopt e-prescribing. The Act requires adoption of this practice by 2011. By upgrading to the Allscripts’ EHR, Jackson Clinic expects to qualify for more than $4 million of stimulus package.
Libertyville, IL-based Allscripts Healthcare Solutions Inc. is a leading provider of clinical software and information solutions meant for physicians. In October 2008, the company merged with Misys Plc, a global applications software and services company, to form Allscripts−Misys Healthcare Solutions. Allscripts faces strong competition from Cerner Corp. (CERN), Merge Healthcare Inc. (MRGE), Quality Systems Inc. (QSII) and MedAssets Inc. (MDAS). 

Currently, we are ‘Neutral’ on Allscripts.
Read the full analyst report on “MDRX”
Read the full analyst report on “CERN”
Read the full analyst report on “MRGE”
Read the full analyst report on “QSII”
Read the full analyst report on “MDAS”
Zacks Investment Research